← Back to Search

Alpha-2 Adrenergic Agonist

Intervention (protocolized clonidine initiation) for Substance Withdrawal

Phase 4
Waitlist Available
Led By Andrea Heifner, MD
Research Sponsored by The University of Texas Health Science Center, Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during time in pediatric intensive care unit (about 5 to 7 days)
Awards & highlights

Study Summary

This trial tests if a drug can reduce symptoms, shorten hospital stays, and reduce costs for sedation in the hospital.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during time in pediatric intensive care unit (about 5 to 7 days)
This trial's timeline: 3 weeks for screening, Varies for treatment, and during time in pediatric intensive care unit (about 5 to 7 days) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with withdrawal as indicated by score on the Withdrawal Assessment Tool (WAT)
Secondary outcome measures
Dexmedetomidine
Pediatric Intensive Care Unit (PICU) length of stay
Sedation costs

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention (protocolized clonidine initiation)Experimental Treatment1 Intervention
A protocol for clonidine initiation will be implemented based on the time on dexmedetomidine and the average hourly dose of dexmedetomidine.
Group II: Usual care (without protocolized clonidine initiation)Active Control1 Intervention
Participants will be observed for dexmedetomidine withdrawal and clonidine will be started at clinician discretion.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Clonidine (protocolized initiation)
2022
Completed Phase 4
~130

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center, HoustonLead Sponsor
903 Previous Clinical Trials
320,849 Total Patients Enrolled
Andrea Heifner, MDPrincipal InvestigatorThe University of Texas Health Science Center, Houston

Media Library

Clonidine (Alpha-2 Adrenergic Agonist) Clinical Trial Eligibility Overview. Trial Name: NCT05575219 — Phase 4
Substance Withdrawal Research Study Groups: Usual care (without protocolized clonidine initiation), Intervention (protocolized clonidine initiation)
Substance Withdrawal Clinical Trial 2023: Clonidine Highlights & Side Effects. Trial Name: NCT05575219 — Phase 4
Clonidine (Alpha-2 Adrenergic Agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05575219 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA sanctioned Intervention (protocolized clonidine initiation) for usage?

"Having already been approved, the safety score of Intervention (protocolized clonidine initiation) was assigned a 3 on Power's scale. This is due to this treatment falling under Phase 4 trial status."

Answered by AI

Is there an open recruitment period for participants in this research?

"Per the information posted on clinicaltrials.gov, this medical study is not actively recruiting patients at this time. The trial was initially shared on October 31st 2022 and saw its last update seven days later; despite that though, there are other similar experiments searching for participants as we speak."

Answered by AI

Who would be the ideal participants for this medical investigation?

"In this research project, 300 participants aged between 4 weeks and 18 years who have been receiving Dexmedetomidine infusion for over 72 hours are eligible."

Answered by AI

Are individuals aged 45 or older being deemed eligible for this research project?

"This medical investigation is seeking participants aged between 4 weeks and 18 years."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Protocolized Initiation of Clonidine to Prevent Dexmedetomidine Withdrawal
Andrea Leigh Heifner 2022. "Protocolized Initiation of Clonidine to Prevent Dexmedetomidine Withdrawal". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05575219.
~51 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top